EP
AGIO icon

Edgestream Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Edgestream Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6M Sell
70,195
-73,536
-51% -$2.23M 0.08% 447
2026
Q1 		$4.86M Sell
143,731
-24,267
-14% -$688K 0.16% 232
2025
Q4 		$4.57M Buy
+167,998
New +$5.89M 0.13% 276
2024
Q3 		– Sell
-42,076
Closed -$1.81M – 821
2024
Q2 		$1.81M Buy
+42,076
New +$1.52M 0.09% 367

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Edgestream Partners's AGIO Position: Q2 2026 in Review

Edgestream Partners reduced its Agios Pharmaceuticals (AGIO) stake by 51% in Q2 2026, selling an estimated $2.23M and leaving 70,195 shares worth $2.6M. The position accounts for 0.08% of the portfolio, ranked #447.

Edgestream Partners first reported a position in AGIO in Q2 2024 and has held it in 4 quarters since. The position peaked at $4.86M in Q1 2026. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Edgestream Partners held 70,195 shares of Agios Pharmaceuticals worth $2.6M as of Q2 2026.
  • Edgestream Partners sold 73,536 Agios Pharmaceuticals shares in Q2 2026, an estimated $2.23M.
  • Agios Pharmaceuticals made up 0.08% of Edgestream Partners's portfolio in Q2 2026, its #447 holding.
  • Edgestream Partners first reported a position in Agios Pharmaceuticals in Q2 2024 and has held it in 4 quarters since.
  • Edgestream Partners's Agios Pharmaceuticals position peaked at $4.86M in Q1 2026.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.